263 related articles for article (PubMed ID: 32843336)
21. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
22. Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3.
Trovato R; Fiore A; Sartori S; Canè S; Giugno R; Cascione L; Paiella S; Salvia R; De Sanctis F; Poffe O; Anselmi C; Hofer F; Sartoris S; Piro G; Carbone C; Corbo V; Lawlor R; Solito S; Pinton L; Mandruzzato S; Bassi C; Scarpa A; Bronte V; Ugel S
J Immunother Cancer; 2019 Sep; 7(1):255. PubMed ID: 31533831
[TBL] [Abstract][Full Text] [Related]
23. Strategies for Increasing Pancreatic Tumor Immunogenicity.
Johnson BA; Yarchoan M; Lee V; Laheru DA; Jaffee EM
Clin Cancer Res; 2017 Apr; 23(7):1656-1669. PubMed ID: 28373364
[TBL] [Abstract][Full Text] [Related]
24. T cells in pancreatic cancer stroma.
Goulart MR; Stasinos K; Fincham REA; Delvecchio FR; Kocher HM
World J Gastroenterol; 2021 Dec; 27(46):7956-7968. PubMed ID: 35046623
[TBL] [Abstract][Full Text] [Related]
25. Of immune checkpoint maladies and remedies: The throwing of jabs in the oncogenic ring of PDAC.
Olaoba OT; Ligali FC; Alabi ZO; Akinyemi AO; Ayinde KS
Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188483. PubMed ID: 33232723
[TBL] [Abstract][Full Text] [Related]
26. Deploying Immunotherapy in Pancreatic Cancer: Defining Mechanisms of Response and Resistance.
Beatty GL; Eghbali S; Kim R
Am Soc Clin Oncol Educ Book; 2017; 37():267-278. PubMed ID: 28561678
[TBL] [Abstract][Full Text] [Related]
27. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
[TBL] [Abstract][Full Text] [Related]
28. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications.
Liu X; Xu J; Zhang B; Liu J; Liang C; Meng Q; Hua J; Yu X; Shi S
Mol Cancer; 2019 Dec; 18(1):184. PubMed ID: 31831007
[TBL] [Abstract][Full Text] [Related]
29. Tumor-Derived Myeloid Cell Chemoattractants and T Cell Exclusion in Pancreatic Cancer.
Vonderheide RH; Bear AS
Front Immunol; 2020; 11():605619. PubMed ID: 33304355
[TBL] [Abstract][Full Text] [Related]
30. Perineural Invasion Reprograms the Immune Microenvironment through Cholinergic Signaling in Pancreatic Ductal Adenocarcinoma.
Yang MW; Tao LY; Jiang YS; Yang JY; Huo YM; Liu DJ; Li J; Fu XL; He R; Lin C; Liu W; Zhang JF; Hua R; Li Q; Jiang SH; Hu LP; Tian GA; Zhang XX; Niu N; Lu P; Shi J; Xiao GG; Wang LW; Xue J; Zhang ZG; Sun YW
Cancer Res; 2020 May; 80(10):1991-2003. PubMed ID: 32098780
[TBL] [Abstract][Full Text] [Related]
31. Upregulation of CD20 Positive B-Cells and B-Cell Aggregates in the Tumor Infiltration Zone is Associated with Better Survival of Patients with Pancreatic Ductal Adenocarcinoma.
Brunner M; Maier K; Rümmele P; Jacobsen A; Merkel S; Benard A; Krautz C; Kersting S; Grützmann R; Weber GF
Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32150869
[TBL] [Abstract][Full Text] [Related]
32. Pancreatic Tumor Microenvironment.
Wang K; He H
Adv Exp Med Biol; 2020; 1296():243-257. PubMed ID: 34185297
[TBL] [Abstract][Full Text] [Related]
33. Monitoring and functional characterization of the lymphocytic compartment in pancreatic ductal adenocarcinoma patients.
Oberg HH; Grage-Griebenow E; Adam-Klages S; Jerg E; Peipp M; Kellner C; Petrick D; Gonnermann D; Freitag-Wolf S; Röcken C; Sebens T; Vogel I; Becker T; Ebsen M; Kabelitz D; Wesch D; Sebens S
Pancreatology; 2016; 16(6):1069-1079. PubMed ID: 27424476
[TBL] [Abstract][Full Text] [Related]
34. Tumoral EHF predicts the efficacy of anti-PD1 therapy in pancreatic ductal adenocarcinoma.
Liu J; Jiang W; Zhao K; Wang H; Zhou T; Bai W; Wang X; Zhao T; Huang C; Gao S; Qin T; Yu W; Yang B; Li X; Fu D; Tan W; Yang S; Ren H; Hao J
J Exp Med; 2019 Mar; 216(3):656-673. PubMed ID: 30733283
[TBL] [Abstract][Full Text] [Related]
35. The Paradoxical Web of Pancreatic Cancer Tumor Microenvironment.
Lafaro KJ; Melstrom LG
Am J Pathol; 2019 Jan; 189(1):44-57. PubMed ID: 30558722
[TBL] [Abstract][Full Text] [Related]
36. Stromal Modulation Reverses Primary Resistance to Immune Checkpoint Blockade in Pancreatic Cancer.
Zhao J; Xiao Z; Li T; Chen H; Yuan Y; Wang YA; Hsiao CH; Chow DS; Overwijk WW; Li C
ACS Nano; 2018 Oct; 12(10):9881-9893. PubMed ID: 30231203
[TBL] [Abstract][Full Text] [Related]
37. Neoadjuvant Therapy Remodels the Pancreatic Cancer Microenvironment via Depletion of Protumorigenic Immune Cells.
Mota Reyes C; Teller S; Muckenhuber A; Konukiewitz B; Safak O; Weichert W; Friess H; Ceyhan GO; Demir IE
Clin Cancer Res; 2020 Jan; 26(1):220-231. PubMed ID: 31585935
[TBL] [Abstract][Full Text] [Related]
38. Perspectives in the treatment of pancreatic adenocarcinoma.
Cid-Arregui A; Juarez V
World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
[TBL] [Abstract][Full Text] [Related]
39. Understanding Tricky Cellular and Molecular Interactions in Pancreatic Tumor Microenvironment: New Food for Thought.
Agostini A; Orlacchio A; Carbone C; Guerriero I
Front Immunol; 2022; 13():876291. PubMed ID: 35711414
[TBL] [Abstract][Full Text] [Related]
40. Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview.
Panchal K; Sahoo RK; Gupta U; Chaurasiya A
Int Immunopharmacol; 2021 Jun; 95():107508. PubMed ID: 33725635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
